Salil Srivastava

Salil Srivastava, PhD, currently serves as the Research Product Team Lead (Director) in the RED CVRI (Cardiovascular, Renal and Immunology) at Bayer, with responsibilities that include leading early discovery projects and collaborating with the Broad Institute on precision targets for innovative drug development in cardiovascular disease. Prior experience includes roles as a Scientist II and Research Scientist I at Bayer and the Broad Institute, focusing on precision cardiology, as well as a Postdoctoral Research Scholar at Novartis Institutes for Biomedical Research, investigating mitochondrial dysfunction in chronic lung diseases. Salil's academic background includes a PhD in Cardiovascular Sciences and a Master of Research from King's College London, where research encompassed the mechanisms of cardiovascular and respiratory diseases.